NMN Supplementation
NMN (nicotinamide mononucleotide) supplementation safely increases NAD+ levels by 40-200%, with potential benefits for mitochondrial function and metabolic health.
NAD+ Elevation
- 100 mg/day: 40% increase
- 300 mg/day: 100% increase
- 500 mg/day: 200% increase
Safety
- No serious adverse events in clinical trials
- Mild GI symptoms at highest doses
- Well-tolerated up to 500 mg/day for 12+ weeks
Dosing
- Typical: 250-500 mg/day
- Sustained NAD+ elevation without tachyphylaxis
- Consider cycling or combining with exercise for synergy
Related registry entry
NAD Precursor Supplementation (nmn-precursors) is the umbrella protocol for NR + NMN trial themes; this page keeps NMN-specific dose framing so all precursor evidence stays discoverable under one conceptual family without scattering duplicate slugs.
Tertiary map
Wikipedia: Nicotinamide mononucleotide (wikipedia-nicotinamide-mononucleotide-overview) plus Wikipedia: Nicotinamide adenine dinucleotide (wikipedia-nicotinamide-adenine-dinucleotide-overview) orient biosynthetic role and regulatory threads—insulin sensitivity, muscle NAD⁺ kinetics, and AE tables remain in PubMed-linked trials on this page.
Evidence
- NMN improves insulin sensitivity in prediabetes
- NMN supplementation improves muscle function in aged adults
- Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults
- Nicotinamide riboside raises NAD+ safely in humans
- Long-term NMN supplementation safety in humans
- Wikipedia: Nicotinamide adenine dinucleotide
- Wikipedia: Nicotinamide mononucleotide